Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades

Phytotherapy Research

Volumn 28, Issue 3, 2014, Pages 423-431

  Kim, Sung Moo ^a   Park, Jeong Ha ^a   Kim, Ki Dong ^a   Nam, Dongwoo ^a   Shim, Bum Sang ^a   Kim, Sung Hoon ^a   Choi, Seung Hoon ^a   Ahn, Kwang Seok ^a   Ahn, Kyoo Seok ^a  

^a Kyung Hee University   (South Korea)

Author keywords

apoptosis; brassinin; PI3K Akt mTOR S6K1; prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BRASSININ; CASPASE 3; CELL PROTEIN; COMPLEMENTARY DNA; HYALURONIC ACID; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHYTOALEXIN; PROTEIN AKT1; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN S6K1; S6 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; NICK END LABELING; NONHUMAN; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

BRASSICA OLERACEA VAR. CAPITATA;

APOPTOSIS; BRASSININ; PI3K/AKT/MTOR/S6K1; PROSTATE CANCER;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; INDOLES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; THIOCARBAMATES; TOR SERINE-THREONINE KINASES;

EID: 84895804774     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5010     Document Type: Article

References (45)

1. Amin AR, Kucuk O, Khuri FR, Shin DM,. 2009. Perspectives for cancer prevention with natural compounds. J Clin Oncol 27: 2712-2725.
2. Banerjee T, Duhadaway JB, Gaspari P, et al,. 2008. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27: 2851-2857.
3. Barlund M, Forozan F, Kononen J, et al,. 2000. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 92: 1252-1259.
4. Bjornsti MA, Houghton PJ,. 2004. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348.
5. Brolin J, Skoog L, Ekman P,. 1992. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate 20: 281-295.
6. Brunet A, Bonni A, Zigmond MJ, et al,. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
7. Campone M, Levy V, Bourbouloux E, et al,. 2009. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 100: 315-321.
8. Chen J, Fang Y,. 2002. A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol 64: 1071-1077.
9. Collado M, Medema RH, Garcia-Cao I, et al,. 2000. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem 275: 21960-21968.
10. Cragg GM, Newman DJ,. 2005. Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79.
11. Csomos P, Zupko I, Rethy B, Fodor L, Falkay G, Bernath G,. 2006. Isobrassinin and its analogues: novel types of antiproliferative agents. Bioorg Med Chem Lett 16: 6273-6276.
12. Dancey JE,. 2006. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 5: 1065-1073.
13. Datta SR, Dudek H, Tao X, et al,. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
14. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB,. 2008. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
15. Feng Y, Wang N, Zhu M, Li H, Tsao S,. 2011. Recent progress on anticancer candidates in patents of herbal medicinal products. Recent Pat Food Nutr Agric 3: 30-48.
16. Gao N, Zhang Z, Jiang BH, Shi X,. 2003. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310: 1124-1132.
17. Garcia-Arenas R, Lin FF, Lin D, et al,. 1995. The expression of prostatic acid phosphatase is transcriptionally regulated in human prostate carcinoma cells. Mol Cell Endocrinol 111: 29-37.
18. Gerhauser C, You M, Liu J, et al,. 1997. Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. Cancer Res 57: 272-278.
19. Hay N,. 2005. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183.
20. Hay N, Sonenberg N,. 2004. Upstream and downstream of mTOR. Genes Dev 18: 1926-1945.
21. Inoki K, Corradetti MN, Guan KL,. 2005. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24.
22. Izutani Y, Yogosawa S, Sowa Y, Sakai T,. 2012. Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells. Int J Oncol 40: 816-824.
23. Kinghorn AD, Su BN, Jang DS, et al,. 2004. Natural inhibitors of carcinogenesis. Planta Med 70: 691-705.
24. Kroemer G, Galluzzi L, Brenner C,. 2007. Mitochondrial membrane permeabilization in cell death. Physiol Rev 87: 99-163.
25. Lebedeva IV, Sarkar D, Su ZZ, et al,. 2003. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 22: 8758-8773.
26. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA,. 2008. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11: 32-50.
27. Martin GS,. 2003. Cell signaling and cancer. Cancer Cell 4: 167-174.
28. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ,. 1991. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65: 701-713.
29. Mehta RG, Liu J, Constantinou A, et al,. 1994. Structure-activity relationships of brassinin in preventing the development of carcinogen-induced mammary lesions in organ culture. Anticancer Res 14: 1209-1213.
30. Mehta RG, Liu J, Constantinou A, et al,. 1995. Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. Carcinogenesis 16: 399-404.
31. Mencher SK, Wang LG,. 2005. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol 5: 3.
32. Mezencev R, Mojzis J, Pilatova M, Kutschy P,. 2003. Antiproliferative and cancer chemopreventive activity of phytoalexins: focus on indole phytoalexins from crucifers. Neoplasma 50: 239-245.
33. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ,. 2001. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142: 4795-4805.
34. Noh WC, Mondesire WH, Peng J, et al,. 2004. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10: 1013-1023.
35. Pedras MS, Montaut S, Suchy M,. 2004. Phytoalexins from the crucifer rutabaga: structures, syntheses, biosyntheses, and antifungal activity. J Org Chem 69: 4471-4476.
36. Pilatova M, Sarissky M, Kutschy P, et al,. 2005. Cruciferous phytoalexins: antiproliferative effects in T-Jurkat leukemic cells. Leuk Res 29: 415-421.
37. Pullen N, Thomas G,. 1997. The modular phosphorylation and activation of p70s6k. FEBS Lett 410: 78-82.
38. Solin T, Kontturi M, Pohlmann R, Vihko P,. 1990. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses. Biochim Biophys Acta 1048: 72-77.
39. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN,. 2009. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35: 148-159.
40. van der Hage JA, van den Broek LJ, et al,. 2004. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer 90: 1543-1550.
41. Wang NS, Unkila MT, Reineks EZ, Distelhorst CW,. 2001. Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-induced cell death. J Biol Chem 276: 44117-44128.
42. Wendel HG, De Stanchina E, Fridman JS, et al,. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337.
43. Wullschleger S, Loewith R, Hall MN,. 2006. TOR signaling in growth and metabolism. Cell 124: 471-484.
44. Yang L, Xie S, Jamaluddin MS, et al,. 2005. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 280: 33558-33565.
45. Zhang M, Latham DE, Delaney MA, Chakravarti A,. 2005. Survivin mediates resistance to anti-androgen therapy in prostate cancer. Oncogene 24: 2474-2482.